Introduction {#s1}
============

Residue-specific posttranslational modifications of histones play essential roles in every aspect of DNA metabolism such as transcription, DNA replication, recombination, and DNA damage repair ([@bib30]). Among these modifications, lysine methylation is the most intriguing due to its remarkable specificity ([@bib15]). For example, methylation of histone H3 lysine 9 (H3K9me) is critical for the assembly of constitutive heterochromatin at repetitive DNA elements, and H3K27me is essential for the formation of facultative heterochromatin at developmentally regulated genes. The methylation is controlled by specific histone methyltransferases and histone demethylases, mutations of which have been associated with many human diseases ([@bib15]; [@bib20]). In comparison, histone genes are not prime suspects for disease-associated mutations, as their high copy number masks the effects of any recessive changes. However, recent high throughput sequencing analyses identified a high incidence of somatic mutations of critical histone lysines into methionine (K-to-M) in multiple cancers ([@bib44]; [@bib46]; [@bib52]; [@bib6]; [@bib45]). The most prominent examples include the association of a K27M mutation in H3.3 (a variant form of H3) with pediatric high-grade glioblastoma, a highly aggressive brain tumor, and the association of a K36M mutation in H3.3 with chondroblastoma, a tumor of the bone. The high frequency of such mutations indicates that they are driver mutations of tumorigenesis.

The role of histone K-to-M mutations in cancer is under intense investigation, but the mechanism is not well understood and controversial. For example, cells containing H3.3K27M show reduced H3K27 trimethylation (H3K27me3) levels on wild type histones, and an H3K27M peptide inhibits polycomb repressive complex 2 (PRC2)-mediated H3K27 methylation in vitro, suggesting that these mutations function as inhibitors of H3K27 methyltransferases ([@bib7]; [@bib11]; [@bib31]; [@bib49]). However, ChIP-seq analyses of cancer cells containing H3.3K27M show that in addition to a global reduction of H3K27me3, a large number of ectopic H3K27me3 peaks are also detected, arguing against a simple inhibitory model ([@bib7]; [@bib11]).

Other histone K-to-M mutations also dominantly block the methylation of their corresponding lysine residues ([@bib12]; [@bib31]; [@bib21]; [@bib33]; [@bib14]), suggesting a similar mechanism of function. Interestingly, mass spectrometry analyses of H3K9M-containing nucleosomes purified from human cells show increased association of an H3K9 demethylase KDM3B, suggesting that recruitment of a demethylase contributes to the effects of H3K9M on H3K9 methylation ([@bib21]).

One of the difficulties in reconciling these results is the complication of the mammalian system. First, there are multiple copies of genes encoding histone H3 and H3.3 ([@bib34]), but it is not clear whether each gene is equivalent in its expression profile. Second, there are multiple methyltransferases that modify each lysine ([@bib15]), and they are differentially inhibited by K-to-M mutations ([@bib14]).

Another difficulty in studying the mechanism of histone K-to-M mutations is the paucity of structural data that explains how the methionine substitution functions to inhibit histone methyltransferases. There are two recent structures of an H3K27M peptide in association with the H3K27 methyltransferase PRC2, which give conflicting interaction details. The structure of *Chaetomium thermophilum* PRC2 reveals that an arginine residue (R26) adjacent to H3K27M occupies the expected lysine-binding channel ([@bib26]), whereas the structure of human PRC2 indicates that the methionine side chain occupies this channel ([@bib27]). There is currently no structure that examines the interaction between other K-to-M mutations and their corresponding histone methyltransferases.

The fission yeast *Schizosaccharomyces pombe* shares highly conserved chromatin modification pathways with mammals, but has key advantages such as relatively facile genetics and single representatives of most key families of mammalian chromatin-modifying factors ([@bib51]). For example, a single histone H3K9 methyltransferase Clr4 is critical for H3K9me across the entire genome and regulates the assembly of heterochromatin ([@bib41]; [@bib37]; [@bib10]). Moreover, there are only three copies of histone H3 genes with identical protein sequences ([@bib36]). The simplicity of the fission yeast system allows us to demonstrate that H3K9M blocks H3K9 methylation through trapping of Clr4 at heterochromatin nucleation centers to prevent its spreading. In addition, H3K9M interacts directly with Clr4 and the interaction is dramatically enhanced by S-adenosylmethionine (SAM), the methyl donor for histone methyltransferases. Moreover, we determined a high-resolution crystal structure of H3K9M in complex with an H3K9 methyltransferase G9a and SAM, which provides a detailed mechanism for the role of methionine in trapping histone methyltransferases. These results provide clear mechanistic insights of histone H3K9M in regulating H3K9me levels.

Results {#s2}
=======

H3K9M dominantly blocks H3K9 methylation and heterochromatin assembly {#s2-1}
---------------------------------------------------------------------

Fission yeast contains three histone H3 genes: *hht1^+^, hht2^+^*, and *hht3^+^*, which produce identical proteins ([@bib36]). We generated Flag-tagged versions of each of these genes at their endogenous chromosomal loci. Western blot analyses showed that the three proteins were expressed at similar levels ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We then introduced the K9M mutation into each histone H3 gene at its endogenous chromosome locus. The three mutant histone H3s were also expressed at similar levels ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

In fission yeast, heterochromatin is mainly present at pericentric region, subtelomeres, and the silent mating-type region, which all contain a similar repetitive DNA element ([@bib16]). These regions contain high levels of histone H3K9 methylation and the transcription of the underlying repeats is repressed. Reporter genes inserted within these repeats, such as *otr::ura4^+^* inserted at the *dh* repeat of pericentric region and *Kint2::ura4^+^* inserted at the *cenH* repeat of the mating-type region ([Figure 1A](#fig1){ref-type="fig"}) ([@bib3]; [@bib17]), are silenced, resulting in cells that only grow weakly on medium without uracil. These cells grow well on medium containing 5-fluoroorotic acid (FOA), which is converted to a toxic form (5-flurouracil) in cells expressing *ura4^+^* ([Figure 1B](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Loss of heterochromatin, such as in *clr4∆*, results in the expression of these reporters and robust cell growth on medium without uracil and decreased growth on FOA-containing medium. Introducing a K9M mutation into any H3 gene resulted in silencing defects similar to that of *clr4∆*, even though there were two other wild type histone H3 genes present ([Figure 1B](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Therefore, we used only *hht3-K9M* for all subsequent analyses. In contrast, an *hht3-K9R* mutation (which is expected to abolish methylation of lysine 9 only on Hht3) had little effect on gene silencing ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), suggesting that the effect of H3K9M is specific.10.7554/eLife.17903.003Figure 1.H3K9M affects H3K9me and heterochromatin assembly.(**A**) Schematic diagrams of reporter genes used. Red bars indicate primers used for ChIP-qPCR and qRT-PCR analyses. (**B**) Left, ten-fold serial dilution analyses of indicated yeast strains grown on indicated media to measure the expression of *otr::ura4^+^*. Right, ChIP analyses of H3K9me3 and H3K9me2 levels at heterochromatin-associated repeats, normalized to *act1^+^*, and qRT-PCR analysis of repeat transcript levels, normalized to *act1^+^*. Data presented is mean ± s.d. of four technical repeats. (**C**) ChIP-seq analysis of H3K9me3 levels across the genome. Data presented is average of two sequencing runs.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.003](10.7554/eLife.17903.003)10.7554/eLife.17903.004Figure 1---figure supplement 1.Western blot analyses of histone H3 and Tubulin levels.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.004](10.7554/eLife.17903.004)10.7554/eLife.17903.005Figure 1---figure supplement 2.Ten-fold serial dilution analyses of indicated yeast strains grown on indicated media to measure the expression of *otr::ura4^+^*.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.005](10.7554/eLife.17903.005)10.7554/eLife.17903.006Figure 1---figure supplement 3.ChIP-seq analyses of H3K9me3 levels at centromeres and telomeres.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.006](10.7554/eLife.17903.006)

ChIP analyses showed that H3K9me3 levels were abolished and H3K9me2 levels were significantly reduced at the heterochromatic *dh* and *cenH* repeats ([Figure 1B](#fig1){ref-type="fig"}). Moreover, transcripts of these repeats were dramatically increased ([Figure 1B](#fig1){ref-type="fig"}). Further ChIP-seq analyses showed that H3K9me3 was reduced to background levels across the entire genome, similar to *clr4∆* ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Unlike the presence of additional H3K27me3 peaks in H3.3K27M containing mammalian cells ([@bib7]; [@bib11]), we did not detect any additional peaks of H3K9me3 in *hht3-K9M* cells. Therefore, H3K9M functions dominant-negatively to regulate H3K9 methylation across the genome.

H3K9M blocks the enzymatic activity of Clr4 {#s2-2}
-------------------------------------------

It has been shown that an H3K27M peptide inhibits the enzymatic activity of the H3K27 methyltransferase PRC2 in vitro ([@bib31]). To examine whether H3K9M also similarly inhibits the enzymatic activity of Clr4, we performed in vitro histone methyltransferase assays using a recombinant Clr4 SET domain (amino acids 190--490), recombinant mono-nucleosomes, and ^3^H labelled S-adenosylmethionine (SAM). The incorporation of radioactively labelled methyl group into histone H3 was significantly reduced in the presence of an H3K9M peptide, suggesting that H3K9M directly inhibits the enzymatic activity of Clr4 in vitro ([Figure 2A](#fig2){ref-type="fig"}).10.7554/eLife.17903.007Figure 2.H3K9M traps Clr4 at nucleation centers to prevent heterochromatin spreading.(**A**) In vitro histone methyltransferase assay with recombinant Clr4 SET domain and recombinant nucleosomes. (**B**) Top, a schematic diagram of the *3xgbs-ade6^+^* reporter. Left, ten-fold serial dilution analyses of indicated yeast strains grown on low adenine media (YE) to measure the expression of *3xgbs-ade6^+^*. Right, ChIP analyses of H3K9me3 levels at *3xgbs,* normalized to *act1^+^*. Data presented is mean ± s.d. of four technical replicates. (**C**) ChIP analysis of Clr4 levels at heterochromatin associated repeats, normalized to *act1^+^*. Data presented is mean ± s.d. of four technical replicates. (**D**) Western blot analysis of Flag-Clr4 protein levels. (**E**) Live cell imaging of cells expressing GFP-Clr4. Scale bar is 1 μm. (**F**) Top, a schematic diagram of the mating type region, with shaded area representing heterochromatin. The PCR fragments used for qPCR analyses are labeled. Bottom, ChIP analysis of Flag-Clr4, H3K9me3, and H3K9me2 levels across the mating type region, normalized to *act1^+^*. Data presented is mean ± s.d. of four technical replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.007](10.7554/eLife.17903.007)10.7554/eLife.17903.008Figure 2---figure supplement 1.Yeast strains were grown on low adenine media (YE) to measure the expression of *3xgbs-ade6^+^*.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.008](10.7554/eLife.17903.008)10.7554/eLife.17903.009Figure 2---figure supplement 2.H3K9M affects mating-type switching.(**A**) Schematic diagram of the mating-type region. *mat2P* and *mat3M* embedded with heterochromatin are used as donors to replace sequence at *mat1*, which determine the mating-type of the cell. (**B**) A competitive PCR analysis to show the relative amount of cells of each mating type. (**C**) Iodine staining of indicated colonies.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.009](10.7554/eLife.17903.009)

To test the inhibitory effects of H3K9M in vivo, we used an *ade6^+^*reporter that is adjacent to 3 copies of Gal4-binding sites (*3xgbs-ade6^+^*). In wild type cells, the reporter gene is expressed, resulting in the formation of white colonies on low adenine medium (YE). In contrast, artificially targeting Clr4 through a Gal4 DNA binding domain silences the reporter, resulting in red colonies ([@bib28]). In *hht3-K9M* cells, the reporter gene was not silenced and no H3K9me3 was detected ([Figure 2B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), suggesting that H3K9M inhibits the enzymatic activity of Clr4 in vivo.

H3K9M traps Clr4 at heterochromatin nucleation centers and prevents Clr4 spreading {#s2-3}
----------------------------------------------------------------------------------

Surprisingly, ChIP analyses showed that Clr4 protein levels were much higher at *dh* and *cenH* repeats in *hht3-K9M* cells ([Figure 2C](#fig2){ref-type="fig"}), even though overall Clr4 protein levels were unchanged ([Figure 2D](#fig2){ref-type="fig"}). Consistently, live-cell imaging analyses showed stronger GFP-Clr4 foci in *hht3-K9M* cells ([Figure 2E](#fig2){ref-type="fig"}). These results suggest that *hht3-K9M* does not affect the targeting of Clr4 to chromatin, but instead traps Clr4 at heterochromatic locations.

Heterochromatin formation is divided into two distinct steps: initiation and spreading ([@bib50]). First, Clr4 is recruited to nucleation centers to initiate H3K9me. H3K9me recruits additional Clr4, through the chromo domain of Clr4 and Swi6 proteins, leading to methylation of adjacent nucleosomes ([@bib18]; [@bib54]; [@bib2]). The repetition of such cycles promotes heterochromatin spreading across large chromosome domains. Both *dh* and *cenH*, which showed higher levels of Clr4, are heterochromatin nucleation centers ([@bib18]). To investigate the effects of H3K9M on heterochromatin spreading, we measured Clr4, H3K9me3, and H3K9me2 levels at the silent mating-type region, which has been extensively used to examine heterochromatin initiation and spreading ([@bib18]). At this region, *cenH* recruits Clr4, which then spreads into a 20 kb domain that are marked by two inverted repeats (*IRL* and *IRR*) ([Figure 2F](#fig2){ref-type="fig"}). We found that in *hht3-K9M* cells, Clr4 was highly enriched at *cenH*, but not at the surrounding regions ([Figure 2F](#fig2){ref-type="fig"}). Furthermore, H3K9me3 was completely abolished across the entire locus, whereas low levels of H3K9me2 were restricted to *cenH* ([Figure 2F](#fig2){ref-type="fig"}). Therefore, H3K9M traps Clr4 at nucleation centers and prevents its spreading into neighboring regions.

Heterochromatin at the silent mating-type locus is essential for the correct choice of donors during mating-type switching, when heterochromatin-embedded *mat2P* or *mat3M* are used as a donor to replace the DNA sequence at *mat1* ([@bib25]) ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). Loss of heterochromatin leads to the predominant use of *mat3M* as a donor, the accumulation of the *M* mating type within a switching competent population, and reduced mating efficiency (indicated by lightly iodine-stained colonies on medium that induces mating and meiosis) ([@bib25]) ([Figure 2---figure supplement 2B and C](#fig2s2){ref-type="fig"}). As expected, *hht3-K9M* cells were predominantly of the *M* mating type and formed lightly iodine-stained colonies similar to *clr4∆* cells ([Figure 2---figure supplement 2B and C](#fig2s2){ref-type="fig"}).

H3K9M enhances binding of Clr4 SET domain to histone H3 tail in a SAM-dependent manner {#s2-4}
--------------------------------------------------------------------------------------

One possible reason for the increased levels of Clr4 at heterochromatin nucleation centers is that Clr4 has a higher affinity for H3K9M. However, the fact that H3K9M-containing nucleosomes outside of heterochromatin failed to trap Clr4 suggests that the interaction between Clr4 and H3K9M is regulated. Clr4 contains a catalytic SET domain as well as a chromo domain that interacts with H3K9me. We found that the chromo domain of Clr4 (1--190) interacted with an H3K9me3 peptide and to a lesser extent with an H3K9me2 peptide, but showed no interaction with the H3K9M peptide ([Figure 3A](#fig3){ref-type="fig"}). In addition, none of the other H3K9me-interacting chromo domains in fission yeast, including Swi6, Chp2, and Chp1 ([@bib42]; [@bib43]), interacted with the H3K9M peptide ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Interestingly, the SET domain of Clr4 (190--490) showed stronger interaction with an H3K9M peptide than a wild type histone H3 tail peptide in a histone methyltransferase buffer (50 mM Tris, pH 8.0, 1 mM EDTA, 50 mM NaCl, 1 mM DTT) supplemented with 100 μM SAM ([Figure 3B](#fig3){ref-type="fig"}). In addition, such interaction was significantly reduced in the absence of SAM ([Figure 3B](#fig3){ref-type="fig"}). The binding is not covalent as Clr4 was removed under stringent washing conditions (data not shown). Moreover, the binding is significantly reduced when S-adenosyl-homocysteine (SAH) was used in place of SAM ([Figure 3C](#fig3){ref-type="fig"}). Furthermore, the SET domain of human H3K9 methyltransferase G9a, which is inhibited by H3K9M in vitro ([@bib31]), also showed stronger binding to the H3K9M peptide than the wild type H3 tail peptide in the presence of SAM ([Figure 3D](#fig3){ref-type="fig"}), suggesting a similar binding mechanism.10.7554/eLife.17903.010Figure 3.H3K9M interacts directly with H3K9 methyltransferases.(**A**) Binding assays with recombinant Clr4 chromo domain and histone peptides in PBS buffer. (**B**, **C**) Binding assays with recombinant Clr4 SET domain and histone peptides in histone methyltransferase buffer supplemented with SAM or SAH. (**D**) Binding assays with recombinant G9a SET domain and histone peptides in histone methyltransferase buffer supplemented with SAM.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.010](10.7554/eLife.17903.010)10.7554/eLife.17903.011Figure 3---figure supplement 1.Binding assays with recombinant GST-tagged chromo domains and histone peptides in PBS buffer.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.011](10.7554/eLife.17903.011)10.7554/eLife.17903.012Figure 3---figure supplement 2.H3K9M functions through the SET domain of Clr4.(**A**) ChIP analyses of H3K9me2 and H3K9me3 levels at *cenH*, normalized to *act1*. Data presented is mean ± s.d. of four technical repeats. (**B**, **C**) ChIP analysis of Clr4 levels at *cenH*, normalized to *act1*. Data presented is mean ± s.d. of four technical repeats.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.012](10.7554/eLife.17903.012)

The binding data suggests that H3K9M exerts its effects through the SET domain of Clr4. To rule out the contribution of the chromo domain of Clr4 to the trapping of Clr4 by H3K9M in vivo, we generated a W31G mutation within the chromo domain, which abolishes its interaction with H3K9me3, but does not affect the enzymatic activity of Clr4 in vitro ([@bib37]; [@bib54]). Similar to previous observations, introducing the W31G mutation at the endogenous *clr4^+^* locus resulted in a severe reduction of H3K9me3, but had little effects on H3K9me2 at *cenH*, the heterochromatin nucleation center of the silent mating-type region ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}) ([@bib2]). The localization of Clr4 to *cenH* was severely reduced in *clr4-W31G* cells, due to the dependence of H3K9me3 for the stable association of Clr4 with heterochromatin ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}) ([@bib54]). Consistent with the idea that H3K9M exerts its effects through the Clr4 SET domain, Clr4-W31G showed enhanced localization at *cenH* in *hht3-K9M* cells ([Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}).

Structure of H3K9M in complex with H3K9 methyltransferase G9a and SAM {#s2-5}
---------------------------------------------------------------------

To understand the molecular details for the interactions between H3K9M and its methyltransferases, we determined a 1.7 Å resolution crystal structure of G9a SET domain in complex with an H3K9M peptide (ARTKQTARMSTGGKA) and SAM ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). Clear electron density was observed for residues 3--12 of the peptide based on the crystallographic analysis ([Figure 4A](#fig4){ref-type="fig"}). We did not include additional SAM during purification and crystallization, but a SAM molecule was observed in the electron density ([Figure 4B](#fig4){ref-type="fig"}), which was likely copurified with the G9a SET domain from *E. coli* lysates.10.7554/eLife.17903.013Figure 4.Structure of the H3K9M-G9a-SAM complex.(**A**) Omit F~o~--F~c~ electron density at 1.7 Å resolution for the H3K9M peptide, contoured at 3σ. (**B**) Omit F~o~--F~c~ electron density at 1.7 Å resolution for SAM, contoured at 3σ. (**C**) Overall structure of G9a (cyan) in complex with the H3K9M peptide (green, stick models) and SAM (magenta). Several zinc ions bound to the protein are shown as pink spheres. The bound position of dimethylated H3K9 peptide to GLP1 is also shown (gray). (**D**) Detailed interactions between G9a (cyan) and the H3K9M peptide (green) near Met9. The structure of GLP1 in complex with the dimethylated H3K9 (Mly9) peptide and SAH is also shown (gray).**DOI:** [http://dx.doi.org/10.7554/eLife.17903.013](10.7554/eLife.17903.013)10.7554/eLife.17903.014Figure 4---figure supplement 1.Structure of the H3K9Nle-G9a-SAM complex.(**A**) Omit F~o~--F~c~ electron density at 1.9 Å resolution for the H3K9Nle peptide, contoured at 3σ. (**B**) Detailed interactions between G9a (cyan) and the H3K9Nle peptide (green) near Nle9. The structure of H3K9M in complex with G9a is also shown for comparison.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.014](10.7554/eLife.17903.014)10.7554/eLife.17903.015Figure 4---figure supplement 2.Sequence alignment of SUV39 family H3K9 histone methyltransferases.Arrows indicate residues of G9a that interact with the methionine side chain. Red arrow indicates Y451 of Clr4. s.p. stands for *Schizosaccharomyces pombe*, d.m. stands for *Drosophila melanogaster*, h.s. stands for *homo sapiens*.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.015](10.7554/eLife.17903.015)10.7554/eLife.17903.016Figure 4---figure supplement 3.Characterization of the Clr4-Y451N mutant.(**A**) In vitro binding assays with recombinant SET domain of Clr4 and histone peptides in the presence of SAM. (**B**) Western blot analysis of Flag-Clr4 levels. (**C**) Mass spectrometry analyses of purified Clr4 complexes. The number of peptides identified and the percentage of protein these peptides cover are indicated. (**D**) Left, ten-fold serial dilution analyses of indicated yeast strains grown on indicated media to measure the expression of *otr::ura4^+^*. Right, ChIP analyses of H3K9me3 and H3K9me2 levels at pericentric *dh* repeats, normalized to *act1^+^*.Data presented is mean ± s.d. of four technical repeats. (**E**) In vitro histone methyltransferase assay with recombinant Clr4 SET domain and histone octamers.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.016](10.7554/eLife.17903.016)

Compared with the structure of another H3K9 methyltransferase G9a-like protein 1 (GLP1) in complex with a dimethylated H3K9 peptide and SAH ([@bib53]), the binding mode of the H3K9M peptide to G9a is essentially identical ([Figure 4C and D](#fig4){ref-type="fig"}). The methionine residue of H3K9M occupies the same binding pocket as the dimethylated lysine residue ([Figure 4D](#fig4){ref-type="fig"}). Five aromatic residues, Tyr1067, Tyr1087, Phe1152, Tyr1154 and Phe1158 surround the methionine side chain. While the dimethylated Lys side chain assumes a fully extended conformation, there is a sharp bend at the sulfur atom of methionine, such that its end methyl group is in closer contact with Tyr1067 and the sulfur is in closer contact with Phe1152 and Tyr1154. The methionine side chain does not extend as deeply into the pocket, and the SAM compound at the bottom of the pocket moves closer to the side chain, by \~0.8 Å compared to the position of SAH in GLP1. SAM does not make direct contributions to the interactions with the methionine side chain, suggesting that its role is to stabilize the structure of the protein. Interestingly, the methyl group of SAM is 3.4 Å away from the side chain of Tyr1154, which is part of the conformational change to stabilize the peptide-binding pocket. In contrast, the G9a-SAH structure does not have this interaction ([@bib53]).

It has been demonstrated that the hydrophobicity of the side chain is critical for H3K27M to inhibit PRC2, and changing methionine to norleucine produces a more potent inhibitor ([@bib31]; [@bib9]). To further understand the contribution of the aliphatic side chain to the interaction between H3K9M and G9a, we performed binding assays with an H3K9-norleucine (H3K9Nle) peptide. We found that H3K9Nle also enhanced binding of the H3 tail peptide to G9a similar to H3K9M (data not shown). We also solved a 1.9Å structure of G9a in complex with an H3K9Nle peptide and SAM ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The structure showed that the norleucine side chain adopts a similar orientation as the methionine side chain, with a bend of the end methyl group ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

To characterize the importance of residues in the binding site for the interactions with the H3K9M peptide, we mutated Tyr451 of Clr4, which is equivalent to Tyr1154 of G9a, to asparagine ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Consistent with our expectations, the binding of Clr4-SET-Y451N to the H3K9M peptide was significantly reduced ([Figure 4---figure supplement 3A](#fig4s3){ref-type="fig"}). We then introduced the Y451N mutation into the endogenous *clr4^+^* locus. The mutant protein was expressed at similar levels as that of wild-type Clr4 and mass spectrometry analysis showed efficient association with other components of the Clr4 complex ([@bib22]; [@bib23]; [@bib24]) ([Figure 4---figure supplement 3B and C](#fig4s3){ref-type="fig"}). The localization of Clr4-Y451N to pericentric *dh* repeats was completely abolished, and no trapping of Clr4 was observed in *hht3-K9M* cells (data not shown). The complete loss of localization of Clr4-Y451N to *dh* repeats is due to the positive feedback mechanism between H3K9 methylation and Clr4 localization ([@bib54]), as the Y451N mutation cannot methylate histones in vitro and in vivo ([Figure 4---figure supplement 3D and E](#fig4s3){ref-type="fig"}). Therefore, although the Y451N mutant demonstrates the critical role of this residue in mediating interaction with H3K9M in vitro, it cannot distinguish in vivo the contribution of its being catalytically inactive or inability to bind H3K9M. We have also mutated two other residues of Clr4 that are expected to interact with H3K9M, Y357N and F383N. However, both of them behaved similarly as Y451N, with complete loss of enzymatic activity in vitro and in vivo, but associated efficiently with other components of the Clr4 complex (data not shown).

Alleviating Clr4 trapping overcomes the inhibitory effects of H3K9M {#s2-6}
-------------------------------------------------------------------

Given that the aromatic residues interacting with the methionine side chain are also required for interaction with the normal lysine substrate, it is not surprising that mutating these residues affected Clr4 enzymatic activity. We therefore explored other ways to relieve trapping of Clr4 by H3K9M. The enzymatic activity of Clr4 in vitro is influenced by modifications of residues adjacent to H3K9 such as phosphorylation of serine 10 ([@bib37]). We suspected that phosphorylated S10 might interfere with the binding of Clr4 with H3K9M peptide. Indeed, in vitro binding of Clr4 SET domain was significantly reduced when an H3K9M peptide containing phosphorylated S10 was used ([Figure 5A](#fig5){ref-type="fig"}). In addition, the in vitro binding of Clr4 to an H3K9MS10D peptide (to mimic the phosphorylated state of S10) was also dramatically reduced ([Figure 5A](#fig5){ref-type="fig"}).10.7554/eLife.17903.017Figure 5.Reduced binding between H3K9M and Clr4 alleviates its inhibitory effects.(**A**) Binding assays with recombinant Clr4 SET domain and histone peptides in histone methyltrasnferase buffer containing SAM. (**B**) Western blot analyses of histone H3 and Clr4 levels. (**C**) ChIP analysis of Clr4 levels at heterochromatin associated repeats, normalized to *act1^+^*. Data presented is mean ± s.d. of four technical repeats. (**D**) Left, ten-fold serial dilution analyses of indicated yeast strains grown on indicated media to measure the expression of *otr::ura4^+^*. Right, ChIP analyses of H3K9me3 and H3K9me2 levels at heterochromatin-associated repeats, normalized to *act1^+^*, and qRT-PCR analysis of repeat transcript levels, normalized to *act1^+^*. Data presented is mean ± s.d. of four technical repeats.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.017](10.7554/eLife.17903.017)10.7554/eLife.17903.018Figure 5---figure supplement 1.S10D has to be present *in cis* with K9M to detoxify H3K9M.Ten-fold serial dilution analyses of indicated yeast strains grown on indicated media to measure the expression of *otr::ura4^+^*.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.018](10.7554/eLife.17903.018)

To examine whether alleviating the trapping of Clr4 by H3K9M can detoxify H3K9M in vivo, we constructed an *hht3-K9MS10D* transgene to mimic the constitutively phosphorylated S10 in vivo. The mutant histone was expressed at similar levels to *hht3-K9M*, and the mutation had no effects on Clr4 protein levels ([Figure 5B](#fig5){ref-type="fig"}). Consistent with our hypothesis, Clr4 was localized to pericentric *dh* repeat in *hht3-K9MS10D* cells at levels very similar to those in wild-type cells, demonstrating that trapping by H3K9M was alleviated by the adjacent S10 modification ([Figure 5C](#fig5){ref-type="fig"}). Moreover, *hht3-K9MS10D* cells showed normal heterochromatin as indicated by silencing of *otr::ura4^+^*, wild type levels of H3K9me3 and H3K9me2 at pericentric repeats, and wild type levels of *dh* RNA transcripts ([Figure 5D](#fig5){ref-type="fig"}). The S10D mutation only detoxified H3K9M when it was present *in cis* with K9M, as introducing an *hht1-S10D* mutation *in trans* could not rescue silencing defects associated with *hht3-K9M* ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

The effects of H3K9M also depends on Clr4 protein levels and the relative concentrations of H3K9M to wild-type H3 {#s2-7}
-----------------------------------------------------------------------------------------------------------------

To further examine the mechanism by which H3K9M regulates H3K9 methylation, we introduced a genomic DNA library into cells containing *hht3-K9M* and *otr::ura4^+^* and looked for clones that conferred resistance to FOA ([Figure 6A](#fig6){ref-type="fig"}). We identified two clones, and sequencing of these two plasmids showed that one contains the *clr4^+^* gene and the other contains histone H3 gene *hht2^+^* ([Figure 6B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). A similar screen with a cDNA library also identified three suppressors that all encode histone H3 genes ([Figure 6B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). These results raise the possibility that the relative dosage of Clr4 and histone H3 is essential for the phenotypes associated with the H3K9M mutation.10.7554/eLife.17903.019Figure 6.The effects of H3K9M on heterochromatin depend on the relative concentrations of H3K9M and Clr4.(**A**) A schematic diagram of the screen procedure for overexpression suppressors of *hht3-K9M*. (**B**) List of genomic and cDNA clones identified in the screen. (**C**, **D**, **E**) Left, ten-fold serial dilution analyses of indicated yeast strains grown on indicated media to measure the expression of *otr::ura4^+^*. Right, ChIP analyses of H3K9me3 and H3K9me2 levels at pericentric *dh* repeat, normalized to *act1^+^*, and qRT-PCR analysis of *dh* repeat transcript levels, normalized to *act1^+^*. Data presented is mean ± s.d. of four technical replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.019](10.7554/eLife.17903.019)10.7554/eLife.17903.020Figure 6---figure supplement 1.Ten-fold serial dilution analyses of indicated yeast strains grown on indicated media to measure the expression of *otr::ura4^+^*.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.020](10.7554/eLife.17903.020)

To further test the effects of Clr4 dosage on *hht3-K9M*, we replaced the *clr4^+^*gene promoter with an inducible *nmt41* promoter. Induction of *clr4^+^* partially rescued the silencing defects associated with *hht3-K9M* ([Figure 6C](#fig6){ref-type="fig"}). The effect is Clr4 dosage dependent, as the stronger *nmt1* promoter provided better rescue and the weaker *nmt81* promoter conferred less rescue ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). In contrast, overexpression of Swi6, an HP1 family protein that binds to H3K9me ([@bib5]; [@bib29]; [@bib37]), could not rescue silencing defects associated with *hht3-K9M* ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}).

To investigate the effects of histone dosage on *hht3-K9M*, we constructed diploid cells containing one or two copies of *hht3-K9M*. Diploid cells containing two copies of *hht3-K9M* are similar in mutant histone dosage as haploid cells containing one copy of *hht3-K9M*, and behaved similarly ([Figure 6D](#fig6){ref-type="fig"}). However, diploid cells containing one copy of *hht3-K9M* resulted in only partial desilencing of *otr::ura4^+^*, with normal H3K9me2 and about a 50% reduction of H3K9me3 ([Figure 6D](#fig6){ref-type="fig"}). Therefore, H3K9M acts in a dosage-dependent manner to affect H3K9 methylation and heterochromatin assembly.

We also tested the effects of histone demethylation in *hht3-K9M* cells. In fission yeast, genetic studies suggest that the JmjC domain protein Epe1 is an H3K9 demethylase, although it should be noted that no demethylase activity of Epe1 is detected in vitro ([@bib48]; [@bib56]; [@bib47]; [@bib4]; [@bib40]). We found that *epe1∆ hht3-K9M* cells partially rescued silencing defects of *otr::ura4^+^*, accompanied by the restoration of H3K9me2 levels and a reduction of pericentric *dh* repeat transcript levels, although H3K9me3 levels were only marginally rescued ([Figure 6E](#fig6){ref-type="fig"}). Therefore, the balance of heterochromatin promoting and destabilizing forces also contribute to the effects of *hht3-K9M*.

Discussions {#s3}
===========

Histone K-to-M mutations are associated with distinct types of cancers and they function in a dominant fashion to block the methylation of lysine residues. However, the molecular mechanism by which these mutations block histone methylation is not well understood. Mammalian cells contain large number of histone genes (and their variants) and histone methyltransferases, which complicate mechanistic analysis. Here, we established an H3K9M model in a much simpler organism, fission yeast, which contains only three histone H3 genes and a single H3K9 methyltransferase Clr4. We found that cells containing one copy of mutant H3K9M completely abolished H3K9me3 on the two other wild copies of histone H3 across the entire genome.

The formation of heterochromatin is divided into two distinct steps: initiation and spreading. The histone methyltransferase Clr4 is first targeted to heterochromatin nucleation centers to initiate H3K9 methylation. The spreading of heterochromatin requires Clr4 mediated H3K9 methylation, which creates binding sites for the chromo domain proteins such as Swi6 and Clr4, thus enhancing the binding of Clr4 to methylate adjacent histones ([Figure 7](#fig7){ref-type="fig"}). We found that Clr4 is trapped at heterochromatin nucleation centers in cells containing H3K9M. The fact that H3K9M enhances the interaction between the SET domain of Clr4 and H3 tail, and that compromising such interaction alleviates the trapping of Clr4 by H3K9M to allow heterochromatin assembly suggest that the trapping of Clr4 is mediated by a direct interaction between H3K9M and the Clr4 SET domain. Since Clr4 enzymatic activity is required for heterochromatin spreading and H3K9M inhibits Clr4 activity, it is also possible that the lack of H3K9me also contributes to the failure of Clr4 spreading in addition to the interaction between Clr4 and H3K9M. The fact that trapping only occurs at heterochromatin nucleation centers suggests that recruitment of Clr4 to H3K9M-containing nucleosomes is essential for trapping of Clr4. Alternatively, other factors might also contribute to the trapping of Clr4 in vivo.10.7554/eLife.17903.021Figure 7.A model of H3K9M dominantly blocking histone H3K9 methylation.In wild type cells, Clr4 is first recruited to heterochromatin nucleation centers to initiate H3K9 methylation. Methylated nucleosomes recruit additional Clr4 to methylate neighboring nucleosomes, leading to heterochromatin spreading. In the end, low levels of Clr4 will cover the entire heterochromatin domain. In H3K9M expressing cells, Clr4 is still recruited to heterochromatin nucleation centers, but will be trapped there due to its interaction with H3K9M containing nucleosomes (yellow). This result in the failure of Clr4 spreading to form heterochromatin domains.**DOI:** [http://dx.doi.org/10.7554/eLife.17903.021](10.7554/eLife.17903.021)

It should be noted that in *hht3-K9M* cells, although H3K9me3 is completely abolished from the entire genome, there are still significant amounts of H3K9me2 present at heterochromatin nucleation centers. Given that the interaction between H3K9M and Clr4 is not covalent, Clr4 is expected to be in an equilibrium between H3K9M bound and free states. Therefore, although Clr4 is trapped at heterochromatin nucleation centers for a majority of the time, there will be short intervals when Clr4 is in the free form and thus available to methylate nearby nucleosomes. Since the *k~cat~* of Clr4 for H3K9me3 is 10 times slower than that of H3K9me2 ([@bib2]), it is much easier for Clr4 to catalyze H3K9me2 than H3K9me3, therefore resulting in a much stronger effects on H3K9me3 than H3K9me2 at heterochromatin nucleation centers, where Clr4 levels are high.

Our structure of G9a in complex with H3K9M and SAM provides the molecular details of how methionine interacts with histone methyltransferases. In contrast to Clr4, which can perform H3K9me3 and regulates heterochromatin assembly, G9a only performs H3K9me2 and mainly acts at euchromatin. Nonetheless G9a is inhibited by H3K9M in vitro ([@bib31]) and its SET domain is highly conserved with that of Clr4. Therefore, we used the G9a-H3K9M-SAM structure as a guide for further analyses. The crystal structure of G9a-H3K9M-SAM complex clearly shows the methionine side chain of H3K9M. It occupies a similar position as that of a normal lysine and interacts with several aromatic residues of G9a through van der Waals interactions. The most obvious difference between the methionine and lysine side chains is the bending of the end methyl group of methionine. When the methionine was substituted with Norleucine, a similar bend of the methyl group was also observed. Such bending increases the diameter of the side chain to enhance van der Waals interactions, therefore explaining the increased binding of H3K9M and H3K9Nle to H3K9 methyltransferases. Although SAM enhanced the binding between H3K9M and H3K9 methyltransferases, SAM does not make strong direct contributions to the interactions with the methionine side chain, suggesting that its role is to stabilize the structure of the protein to properly form the binding pocket. In addition, the position of SAM is incompatible with dimethylated lysine within G9a, suggesting that the binding of SAM helps release the wild type histone H3 tail after methylation reactions. Therefore, the structure explains why SAM is critical for stabilizing the interaction between H3K9M and H3K9 methyltransferases.

The binding mode of H3K9M-G9a-SAM differs from the structure of H3K27M in complex with *Chaetomium thermophilum* PRC2, in which an adjacent arginine occupies the lysine channel ([@bib26]), even though H3K9M also has an adjacent arginine. It is consistent with the structure of the H3K27M-human PRC2 complex, with methionine occupying the expected lysine-binding channel ([@bib27]). Such a binding state can explain the fact that all known K-to-M mutations, even those without adjacent arginine (such as H3K36M and H3K4M), inhibit the enzymatic activity of their corresponding histone methyltransferases ([@bib12]; [@bib31]; [@bib21]). The high conservation of aromatic residues mediating interactions with the methionine side chain suggests that other K-to-M mutations might function in a similar fashion. Indeed, mutant histones show increased association with histone methyltransferases in vivo and in vitro ([@bib7]; [@bib11]; [@bib27]; [@bib33]; [@bib14]). The strengthened interaction might similarly prevent the turnover of these enzymes to block the methylation of other wild type histones.

Finally, our results also suggest several ways to detoxify the effects of H3K9M. First, the effect of H3K9M can be modulated by a modification on the K9M containing histone tail that affects its interaction with Clr4. It is interesting to note that H3K27 is also adjacent to a serine (S28). S28 phosphorylation reduced the inhibitory effects of H3K27M on PRC2 activity in vitro, and introduction of a H3K27MS28E mutant reduced the effects of H3K27M on H3K27me3 in vivo ([@bib9]). Another way to modulate the effects of H3K9M is through changing Clr4 levels or mutant-to-wild type histone ratios, suggesting that the effects of H3K9M are exerted through a direct competition between H3K9M and normal H3 for a limited pool of Clr4 protein. Finally, tipping the balance between heterochromatin assembly and disassembly, such as the deletion of putative histone demethylase Epe1, can also partially detoxify H3K9M. This is consistent with an earlier observation that inhibiting H3K27 demethylase JMJD3 alleviates the effects of H3K27M mutation in glioblastoma ([@bib19]). Given the similarities between different histone K-to-M mutations, it is highly likely that these approaches can be used to detoxify other histone K-to-M mutations as well.

Materials and methods {#s4}
=====================

Fission yeast strains and genetic analyses {#s4-1}
------------------------------------------

Yeast strains containing epitope tagged histones and their mutants were generated by a PCR-based module method. All other strains were constructed through genetic crosses. A list of yeast strains used is provided in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}. For serial dilution plating assays, ten-fold dilutions of a mid log-phase culture were plated on the indicated medium and grown for 3 days at 30°C.

Chromatin immunoprecipitation (ChIP) analyses {#s4-2}
---------------------------------------------

Log-phase yeast cells were incubated at 18°C for 2 hours and then fixed for 30 minutes in 3% freshly made formaldehyde. The crosslinking reaction was stopped by the addition of 2.5 M Glycine to make a final concentration of 0.125 M. The cells were pelleted and washed with PBS (phosphate buffered saline) before resuspended in ChIP lysis buffer (50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1% Triton X-100, 0.1% Deoxycholate supplemented with cOmplete protease inhibitors cocktail (Roche)). Ice cold glass beads were added and the mixtures were vigorously disrupted in a beadbeater. The lysates were collected and subjected to sonication to reduce chromatin size to 500--1000 base pairs. The cleared cell lysates were incubated with antibodies: H3K9me3 (Abcam), H3K9me2 (Abcam), and Flag (Sigma) over night at 4°C. Protein G beads were then added to isolate the antibodies and associated chromatin fragments. The beads were then washed with ChIP lysis buffer twice, ChIP lysis buffer containing 0.5 M NaCl, Wash buffer (10 mM Tris, pH 8.0, 250 mM LiCl, 0.5% NP-40, 0.5% Deoxycholate, 1 mM EDTA), and TE (50 mM Tris pH 8.0, 1 mM EDTA). The bound chromatin fragments were eluted with TES (50 mM Tris pH 8.0, 1 mM EDTA, 1% SDS) and the crosslinking was reversed by incubating at 65°C overnight. The protein DNA mixture were then subjected to proteinase K treatment and phenol:chloroform extraction before the DNA was precipitated by ethanol.

Quantitative real-time PCR (qPCR) was performed with Maxima SYBR Green qPCR Master Mix (Fermentas) in a StepOne Plus Real Time PCR System (Applied Biosystems). DNA serial dilutions were used as templates to generate a standard curve of amplification for each pair of primers, and the relative concentration of target sequence was calculated accordingly. An *act1* fragment was used as a reference to calculate the enrichment of ChIP over WCE for each target sequence. A list of DNA oligos used is provided in [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}.

For ChIP-seq, DNA samples were prepared according to TruSeq ChIP sample preparation guide (Illumina) and sequenced on the Illumina HiSeq 2500 system by 100 bp paired-end sequencing. The raw reads were trimmed by Trimmomatic (v0.35) ([@bib8]) to remove potential adapter contamination and regions with bad sequencing qualities. The trimmed reads were aligned to the *S. pombe* reference genome (Ensembl version: ASM294v2.29) by bwa (0.7.12-r1039) (<http://bio-bwa.sourceforge.net/>). The resulting sam files were further processed by Samtools (v1.2) ([@bib32]), picard-tools (v2.0.1) (<http://broadinstitute.github.io/picard/>) and GATK (v3.5) ([@bib35]) for indexing, sorting, removing PCR duplicates, and local-realignment. The per-based mapping depth was calculated by bedtools (v2.25.0) ([@bib39]) and the sliding window plots (window size = 100 bp, step size = 50 bp) were created by in-house Perl and R scripts. We also employed MACS (v1.4.2) ([@bib55]) to contrast each ChIP sample versus WCE sample for peak calling.

RNA analyses {#s4-3}
------------

Total cellular RNA was isolated from log-phase cells using MasterPure yeast RNA purification kit (Epicentre) according to the manufacturer's protocol. Quantification with real time RT-PCR was performed with Power SYBR Green RNA-to-CT one-step Kit (Applied Biosystems). RNA serial dilutions were used as templates to generate a standard curve of amplification for each pair of primers, and the relative concentration of the target sequence was calculated accordingly. An *act1* fragment served as a reference to normalize the concentration of samples. The concentration of each target gene in wild type was arbitrarily set to 1 and served as reference for other samples.

In vitro histone methyltransferase and peptide binding assays {#s4-4}
-------------------------------------------------------------

Histone peptides (H3, 1--21) with a C-terminal biotinylated lysine were synthesized by Anaspec at 90% purity and confirmed by mass spectrometry analyses. Clr4 chromo domain (1--190) and SET domain (190--490) were cloned into a pGEX vector. Expression plasmid for GST tagged Swi6, Chp2, and Chp1 chromo domains are gifts from Dr. Jun-ichi Nakayama. The GST fusion proteins were purified with Glutathione beads (GE Healthcare) according to the manufacturer's protocol.

To examine the enzymatic activity of Clr4 mutants, histone methyltransferase assays were performed with 0.5 µg of recombinant Clr4 SET domain and 2.6 µg of Hela histones in a histone methyltransferase buffer (50 mM Tris, pH 8.0, 1 mM EDTA, 0.5 mM DTT) supplemented with ^3^H-SAM for 30 minutes at 30°C. The samples were resolved by SDS-PAGE and subjected to Coomassie staining to visualize the proteins and then treated with EN3HANCE (Perkin Elmer) to visualize labeled substrates.

To examine the inhibitory effects of H3K9M peptide, 0.1 µg recombinant SET domain of Clr4 was incubated with 1 µg recombinant human nucleosomes in a methyltransferase buffer (100 mM Tris, pH 8.8, 100 mM KCl, 5% glycerol, 1 mM MgCl~2~, 20 µM ZnSO~4~, 10 mM β-mercaptoethanol) supplemented with 10 µM non-radioactive SAM and 2 µM \[^3^H\]-labeled SAM for 30 minutes at 30°C. The H3K9M peptide was incubated with Clr4 SET domain for 15 minutes at 30°C before the addition of mono-nucleosomes.

Protein binding assays with recombinant chromo domains were performed by incubating recombinant proteins with biotinylated histone peptides in PBS buffer for 30 minutes at 30°C. Streptavidin beads were added to isolate biotinylated peptide and associated proteins. The beads were washed three times with PBS buffer. The proteins bound to the beads were resolved by SDS-PAGE and stained with Coomassie blue.

Protein binding assays with recombinant SET domains were performed by incubating recombinant proteins in histone methyltransferase buffer (50 mM Tris, pH 8.0, 50 mM NaCl, 1 mM EDTA, 0.5 mM DTT) supplemented with 50 µM SAM or SAH for one hour at 30°C. Streptavidin beads were added to isolate biotinylated peptide and associated proteins. The beads were washed three times in histone methyltransferase buffer before resolved by SDS-PAGE and stained with Coomassie blue. To examine whether the binding was covalent, ChIP lysis buffer (50 mM HEPES-KOH, pH7.5, 500 mM NaCl, 1% Triton X-100, 0.1% sodium deoxycholate) was used to perform the washes.

Protein expression and purification {#s4-5}
-----------------------------------

The expression and purification of the SET domain of human G9a (residues 913--1193) followed a published procedure ([@bib53]). The expression plasmid (gift of Prof. Matthieu Schapira) was transformed into competent cells and induced using 0.25 mM isopropyl-1-thio-D-galactopyranoside when A600 is 0.7. After incubation overnight at 16°C, the cells were harvested and resuspended in lysis buffer (20 mM Tris (pH 8.0), 250 mM NaCl, and 5% (v/v) glycerol) supplemented with 2 mM β-mercaptoethanol, 0.1% Igepal and 1 mM phenylmethylsulfonyl fluoride and lysed with ultrasonication. The lysate was incubated with Ni-NTA resin (QIAGEN) and washed with 10 column volume lysis buffer containing 50 mM imidazole. Bound protein was eluted with lysis buffer containing 250 mM imidazole, and was digested overnight with thrombin to remove the 6xHis-tag. After concentration, the protein was loaded onto a Superose 6 column (GE Healthcare) equilibrated with gel filtration buffer (20 mM Tris (pH 8.0), 150 mM NaCl). The fractions of the protein peaks were collected and concentrated.

Crystallization {#s4-6}
---------------

The protein was incubated with the H3K9M peptide at a molar ration of 1:10 on ice for 30 min, and the sample was then set up for crystallization with the hanging-drop vapor diffusion method at 20°C. The reservoir solution contained 0.1 M Bis-Tris propane (pH 7.5), 18% (w/v) PEG3350, 0.2 M NaF, and 5% (v/v) ethylene glycol. Using mother liquor supplemented with 15% (v/v) glycerol as cryo-protectant, the crystals were frozen in liquid nitrogen before data collection.

Data collection and structure determination {#s4-7}
-------------------------------------------

X-ray diffraction data were collected at 100K at NE-CAT beamline 24-ID-C of Advanced Photon Source (APS) at Argonne National Laboratory and processed using program HKL2000 ([@bib38]). The structure was solved through molecular replacement using Phaser-MR in program PHENIX ([@bib1]). The structure refinement was carried out using PHENIX, and manual model building with Coot ([@bib13]).

Accession numbers {#s4-8}
-----------------

ChIP-seq data is available at Arrayexpress under accession number E-MTAB-4776. The atomic coordinates have been deposited at the Protein Data Bank, with accession codes 5T0K (Clr4-H3K9M-SAM) and 5T0M (Clr4-H3K9Nle-SAM).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, Jerry Workman, is a member of our Board of Reviewing Editors, and the evaluation has been overseen Jessica Tyler as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This is a timely manuscript that seeks to explain how an H3K9M mutation in a single copy of histone genes hinders methylation of WT H3 in the same cell. The data support a model whereby the H3K9M mutation traps the Clr4 methyltransferase preventing its spreading to form heterochromatic domains. This is a novel mechanism based on genetics in *S. pombe* and crystallography.

Summary:

Recently, histone H3.3K27M and H3.3K36M mutations have been found in high-grade pediatric brain tumors and chondroblastoma of bone, respectively. In addition, it has been shown that expression of histone K to M mutant transgenes in human cells leads to the reduction in methylation of corresponding lysine residues on endogenous histones. However, the mechanism of action of histone K to M mutant remains in debate in the field. The manuscript by Shan et al. utilizes fission yeast as the model system to address the mechanism whereby H3K9M affects H3K9 methylation. Expression of H3K9M from one of the three histone H3 genes results in complete loss of H3K9me3 and silencing at heterochromatin. Interestingly, Clr4, the only enzyme for H3K9 methylation remains bound to nucleation center, where H3K9me2, but not H3K9me3, was detected. In vitro, Clr4 and G9a bound to H3K9M peptides with higher affinity than the corresponding wild type H3. They also solved the crystal structure of G9a catalytic domain in complex with H3K9M peptide. Based on the structure, they tested several possible ways to relieve the inhibition of Clr4 activity by H3K9M proteins.

The authors build a model in which the block in heterochromatin assembly is mediated solely via sequestration of Clr4 by its SET domain binding to H3K9M. I am not totally convinced that this is the case, and would like to see further work done to rule out contribution of Clr4 CD in K9M mediated disruption of silencing.

Finally, G9a structure with K9M peptide was recently published (Jayaram et al. 2016 PNAS) including demonstration of importance of SAM for conformational change, which reduces impact of some of this story.

Overall, this manuscript is well written, interesting, timely and will help resolve the debate in the field. We have the following suggestions to improve the manuscript.

Essential revisions:

1\) It is a bit disconcerting that when H3K9M is supposed to inhibit Clr4 activity in vivo, that such inhibition could not be observed in vitro. While it is always possible that it won\'t work in vitro, it does suggest that other components in vivo are involved reducing enthusiasm for the author's simple model. Perhaps more effort should be devoted to optimizing the biochemical assay. It is stated that H3K9M peptide cannot inhibit enzymatic activity of Clr4 in vitro when peptides and octamers were used as substrates. Did the authors use mononucleosomes as substrates?

2\) Another point regarding the in vitro methylation assays. Was recombinant full length Clr4 tried? (it has HMT activity: Nakayama et al. Sci 2001). I have a nagging feeling that Clr4\'s CD could be critical to the suppression of Clr4 activity by K9M. It is known that the detailed mechanism of action of Clr4 differs from Suv39h1 (compare Al-Sady et al. Mol Cell 2013 with Muller et al., Nat Chem Biol 2016) and so presumably also G9a (which only performs dimethylation and not trimethylation). As the chromodomain is also suggested to be involved in heterochromatin spreading it is important that the authors determine the extent that loss of chromodomain interaction contributes to the H3K9M phenotypes.

3\) Something else to consider is that *pombe* has 4 CD proteins that can bind H3K9 when methylated. The authors perform binding studies with Clr4 CD- and show as previously reported that it has higher affinity for K9me3 than me2 peptides. They see no interaction with H3K9M. But there are some inconsistencies with description of this data such as they say that SET domain interactions with H3K9M (which they can detect) are not covalent as they are disrupted by 500 mM Nacl wash with detergents, but list this same buffer as their wash buffer for the pull down experiments.

Do other CD proteins bind K9M and does this contribute to the heterochromatin defects in K9M expressing cells?

4\) Why is K9me2 detected at \"nucleation\" points, but not K9me3? If the model is that K9M binds and blocks Clr4\'s SET domain, wouldn\'t the expected result be equivalent loss of all forms of methylated H3? Does this just then reflect a difference in the normal levels of the different methylated forms of H3 in cells or reflect a difference in the sensitivity of detection of the different methylated forms in the ChIP assays? Or is it telling us something about the mechanism of inhibition of HMT activity. I think this is a case where quantitative spike in of dNucs could be useful- or at least referencing of others work in this area (Al-Sady et al. Mol Cell 2013) who show that the dimethylated K9 state is predominant in *pombe*.

5\) The only piece of evidence presented that the inhibition is mediated via the SET domain of Clr4 is disruption of silencing of a GAL4-reporter in K9M expressing cells that have GBD-Clr4 tethered (that lacks the CD of Clr4). Very little data is shown for this (the system shows variegation in WT cells, and it is difficult to assess what is going on in the population when the color of single colonies are shown). Fields of colonies should be presented. Similarly, were \"white\" and \"red\" colonies picked for the ChIP analysis or was this from a mixed population?

I think a nice experiment that would help cement that the K9M effect is via Clr4 SET domain would be demonstration that this GBD-Clr4 fusion is recruited to nucleation sites at sites of heterochromatin in cells lacking the GBD reporter. This would reinforce that the mechanism relies on SET domain interaction with K9M.

Alternately, there are 2 CD mutant versions of Clr4 (in Nakayama et al. 2001) that in WT cells retain HMT activity at centromeres. These are aromatic cage mutants of the CD- so if K9M is binding via the CD -- these mutants may be insensitive to K9M-mediated disruption of centromeric silencing.

10.7554/eLife.17903.026

Author response

*Summary:*

*Recently, histone H3.3K27M and H3.3K36M mutations have been found in high-grade pediatric brain tumors and chondroblastoma of bone, respectively*

\[...\]

*The authors build a model in which the block in heterochromatin assembly is mediated solely via sequestration of Clr4 by its SET domain binding to H3K9M. I am not totally convinced that this is the case, and would like to see further work done to rule out contribution of Clr4 CD in K9M mediated disruption of silencing.*

We thank the reviewers for their constructive suggestions. In the revised manuscript, we have additional evidence to rule out the contribution of Clr4-CD. First, we optimized in vitro histone methyltransferase assays and showed that the Clr4 SET domain is inhibited by H3K9M ([Figure 2A](#fig2){ref-type="fig"}). Second, the Clr4 chromo domain mutant (W31G) is also trapped by H3K9M at heterochromatin nucleation centers in vivo ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). These new data, together with in vitro binding assays showing that the SET domain, but not the CD, binds to H3K9M, clearly demonstrate that H3K9M function through the SET domain of Clr4.

*Finally, G9a structure with K9M peptide was recently published (Jayaram et al. 2016 PNAS) including demonstration of importance of SAM for conformational change, which reduces impact of some of this story.*

Our work is completely independent of that report (which was contributed to PNAS by an NAS member, submitted for review on March 16 and accepted on April 8. Our manuscript was already under consideration for publication at that time (at a different journal)), and reveals mechanistic insights in a living organism well beyond the structural information, which are not available in that report.

*Overall, this manuscript is well written, interesting, timely and will help resolve the debate in the field. We have the following suggestions to improve the manuscript.*

*Essential revisions:*

*1) It is a bit disconcerting that when H3K9M is supposed to inhibit Clr4 activity* in vivo*, that such inhibition could not be observed* in vitro*. While it is always possible that it won\'t work* in vitro*, it does suggest that other components* in vivo *are involved reducing enthusiasm for the author's simple model. Perhaps more effort should be devoted to optimizing the biochemical assay. It is stated that H3K9M peptide cannot inhibit enzymatic activity of Clr4* in vitro *when peptides and octamers were used as substrates. Did the authors use mononucleosomes as substrates?*

We optimized conditions for in vitro histone methyltransferase assays and found that the H3K9M peptide inhibits Clr4 enzymatic activity when recombinant mono-nucleosome was used as substrates. One likely reason for the stronger inhibitory effects on nucleosomes is that the activity of Clr4 is much weaker on nucleosomes compared with histone octamers, thus providing less opportunity for Clr4 to complete methylation reactions when Clr4 is in an H3K9M-free state.

*2) Another point regarding the* in vitro *methylation assays. Was recombinant full length Clr4 tried? (it has HMT activity: Nakayama et al. Sci 2001). I have a nagging feeling that Clr4\'s CD could be critical to the suppression of Clr4 activity by K9M. It is known that the detailed mechanism of action of Clr4 differs from Suv39h1 (compare Al-Sady et al. Mol Cell 2013 with Muller et al., Nat Chem Biol 2016) and so presumably also G9a (which only performs dimethylation and not trimethylation). As the chromodomain is also suggested to be involved in heterochromatin spreading it is important that the authors determine the extent that loss of chromodomain interaction contributes to the H3K9M phenotypes.*

The new histone methyltransferase assay in [Figure 2A](#fig2){ref-type="fig"} shows that the SET domain of Clr4 is inhibited by H3K9M. Furthermore, our binding data in [Figure 3A](#fig3){ref-type="fig"} showed that the Clr4-SET domain, but not the Clr4-CD, binds to an H3K9M peptide. These results demonstrate that the effect of H3K9M is through the SET domain. We did not use full length Clr4 protein because it is not expressed well in *E. coli*. Given that our new data has already ruled out the possibility that Clr4-CD contributes to the phenotypes associated with the H3K9M mutation, it is not necessary to further test the full length Clr4.

We also examined the localization of Clr4 chromo domain mutant W31G, as suggested by the reviewer. We found that Flag-Clr4-W31G levels at *cenH* increased in *hht3-K9M* cells (new [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Together with our biochemical analysis showing that H3K9M peptide interacts directly with the SET domain, these data support our main conclusion that H3K9M functions through the SET domain rather than the chromo domain of Clr4.

The difference between Clr4 and SUV39H1 mainly lies at a region at the N-terminus of SUV39H1, which is absent from Clr4. Since we have shown that the SET domain is inhibited by H3K9M in vitro, and that the chromo domain mutant is trapped at heterochromatin nucleation center by H3K9M, such a difference is irrelevant to the study here.

*3) Something else to consider is that pombe has 4 CD proteins that can bind H3K9 when methylated. The authors perform binding studies with Clr4 CD- and show as previously reported that it has higher affinity for K9me3 than me2 peptides. They see no interaction with H3K9M. But there are some inconsistencies with description of this data such as they say that SET domain interactions with H3K9M (which they can detect) are not covalent as they are disrupted by 500 mM Nacl wash with detergents, but list this same buffer as their wash buffer for the pull down experiments.*

*Do other CD proteins bind K9M and does this contribute to the heterochromatin defects in K9M expressing cells?*

The high salt buffer with detergent was only used to test whether the H3K9M-Clr4 interaction was covalent, not in any other binding assays. In the revised manuscript, we listed the buffer used for each binding assay in figure legends to avoid any confusion.

As suggested by the reviewer, we performed binding assays with recombinant chromo domains of the other three chromo domain containing proteins (Swi6, Chp1, and Chp2) involved in heterochromatin formation ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). These proteins all interacted with H3K9me2 and H3K9me3 peptides, but not with H3K9M peptide. The experiments in [Figure 6](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, in which overexpression of Clr4, but not Swi6, could not rescue H3K9M phenotypes, further support the idea that H3K9M functions through Clr4 instead of chromo domain proteins such as Swi6.

*4) Why is K9me2 detected at \"nucleation\" points, but not K9me3? If the model is that K9M binds and blocks Clr4\'s SET domain, wouldn\'t the expected result be equivalent loss of all forms of methylated H3? Does this just then reflect a difference in the normal levels of the different methylated forms of H3 in cells or reflect a difference in the sensitivity of detection of the different methylated forms in the ChIP assays? Or is it telling us something about the mechanism of inhibition of HMT activity. I think this is a case where quantitative spike in of dNucs could be useful- or at least referencing of others work in this area (Al-Sady et al. Mol Cell 2013) who show that the dimethylated K9 state is predominant in pombe.*

We have added a paragraph in the Discussion section (third paragraph) regarding the different effects of H3K9M on H3K9me3 and H3K9me2. Our structural and biochemical analyses indicate that H3K9M enhances binding of histone H3 to Clr4, but the binding is not covalent. Therefore, Clr4 should be in an equilibrium between H3K9M-bound and free states. Al-Sady et al., 2013 have beautifully demonstrated that the *k~cat~*of Clr4 to catalyze H3K9me3 is 10 times slower than that of H3K9me2, resulting in much higher in vivo H3K9me2 levels than H3K9me3. Due to the slow rate of H3K9me3, the time interval that Clr4 falls off H3K9M might only allow it to perform H3K9me2, but difficult to complete H3K9me3.

Spike in of dNucleosomes is used to calculate the absolute levels of H3K9me3 and H3K9me2 in cells. Given that we are only comparing the relative levels of H3K9me3 and H3K9me2 between wild type and *hht3-K9M* cells, we believe that the experiments with dNucleosomes are unnecessary. We referenced Al-Sady et al. as suggested by the reviewer.

*5) The only piece of evidence presented that the inhibition is mediated via the SET domain of Clr4 is disruption of silencing of a GAL4-reporter in K9M expressing cells that have GBD-Clr4 tethered (that lacks the CD of Clr4). Very little data is shown for this (the system shows variegation in WT cells, and it is difficult to assess what is going on in the population when the color of single colonies are shown). Fields of colonies should be presented. Similarly, were \"white\" and \"red\" colonies picked for the ChIP analysis or was this from a mixed population?*

The system we used only showed very little variation. We included pictures of fields of colonies in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In the absence of GBD-Clr4-∆CD, all colonies are white. In the presence of GBD-Clr4-∆CD, the vast majority of colonies are red, with only a very small number of white colonies. In the presence of GBD-Clr4-∆CD and Hht3-K9M, all colonies are white.

Our ChIP analyses were performed with mixed population of cells without any selection.

*I think a nice experiment that would help cement that the K9M effect is via Clr4 SET domain would be demonstration that this GBD-Clr4 fusion is recruited to nucleation sites at sites of heterochromatin in cells lacking the GBD reporter. This would reinforce that the mechanism relies on SET domain interaction with K9M.*

*Alternately, there are 2 CD mutant versions of Clr4 (in Nakayama et al. 2001) that in WT cells retain HMT activity at centromeres. These are aromatic cage mutants of the CD- so if K9M is binding via the CD -- these mutants may be insensitive to K9M-mediated disruption of centromeric silencing*

As suggested by the reviewer, we examined the chromo domain mutant W31G of Clr4. We found that Flag-Clr4-W31G levels at the silent mating-type region heterochromatin nucleation center *cenH* increased in *hht3-K9M* cells (new Figure 2---figure supplement 3). This result further supports our main conclusion that H3K9M functions through the SET domain rather than the chromo domain of Clr4.

[^1]: These authors contributed equally to this work.
